found Documents: 443

Announcements & Press Releases, Oncology / Immunology | 16 Jul 2021

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

2 items

– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Jul 2021

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, July 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and high

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 12 Jul 2021

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Monday, July 12, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of the over-allotment option of the Global Offering. Th

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Jul 2021

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China

2 items

Hong Kong, Shanghai and Florham Park, NJ — Tuesday, July 6, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL‑295, its investigative and highly selective oral inhibitor of ERK, which

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Group | 2 Jul 2021

HUTCHMED to Announce 2021 Half-Year Financial Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, July 2, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jul 2021

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

2 items

– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China – Hong Kong, Shanghai & Florham Park, NJ — Thursday,

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Group | 30 Jun 2021

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 30, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing of its ordinary shares (“Shares”) on the Main Board of the Stoc

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Group | 23 Jun 2021

HUTCHMED Announces Pricing of Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Wednesday, June 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its global offering (the “Global Offering”) of 104,000,000 n

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Jun 2021

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

2 items

– First selective MET inhibitor approval in China in this setting – – First regulatory approval for the oral, potent and selective MET tyrosine kinase inhibitor – Hong Kong, Shanghai & Florham Park, NJ —Tuesday, June 22, 202

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Jun 2021

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

2 items

– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancreatic NET – Hong K

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 18 Jun 2021

HUTCHMED Launches Hong Kong Initial Public Offering

1 item

Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of its Hong Kong public offering (the “Hong Kong Public Offering”),

View Announcement (PDF)

Announcements & Press Releases, Group | 20 May 2021

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

1 item

– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 8 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and provide a corporate update – Hong Kong,

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China

HUTCHMED to Announce 2021 Half-Year Financial Results

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

HUTCHMED Announces Pricing of Global Offering

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

HUTCHMED Launches Hong Kong Initial Public Offering

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

HUTCHMED to Attend Upcoming Investor Conferences

Change of Company Name

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies

2020 Annual Report and Notice of Annual General Meeting

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

Chi-Med becomes HUTCHMED

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference

Chi-Med Hosts Ground-breaking Ceremony for a Large-Scale Manufacturing Plant in Zhangjiang, Shanghai

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors

Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China

Chi-Med to Announce 2020 Half-Year Financial Results

Chi-Med Announces US$100 Million Equity Investment by General Atlantic

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations